Wound treatment


Wound treatment

Vivostat® recommends using a bioactive autologous platelet enriched fibrin in wound treatment. Vivostat® PRF contains the essential growth factors that are crucial when treating challenging wounds and burns.

The combination of platelets and fibrin in Vivostat® PRF is unique. Not only does the fibrin protect the platelets from proteolytic degradation, but it also ensures a slow release of growth factors over time. Also, the autologous solution polymerizes immediately upon application, which means that the platelets stay where they are applied.

Vivostat® PRF has shown almost unbelievable results when it comes to:

  • Chronic wounds
  • Diabetic ulcers
  • Venous ulcers
  • Pressure ulcers
    • Surgical wounds
    • Skin grafts
  • Burns
    • Skin grafts
    • Faces/necks/hands

For decades fibrin sealant has been used for burns as a scaffold for re-epithelialization. Vivostat® PRF provides this scaffold and combines it with a high concentration of platelets relevant for tissue regeneration.

The high concentration of fibrin found in Vivostat® PRF, furthermore, acts as a glue enabling the surgeon to use Vivostat® PRF for graft fixations. The solution also acts as a haemostatic reducing the risk of haematoma formation, which may cause graft loss. Any remaining Vivostat® PRF can be applied to the graft harvest site to speed up tissue regeneration or it can be split up in several dozes and freeze for continuous treatment over a period.

For orthopeadic surgery wounds we recommend using ArthroZheal®.

main advantages using vivostat®


One of the many unique properties of the Vivostat® System is the possibility to co-apply. With the Vivostat® Co-Delivery system you can apply substances (e.g. BMAC, stem cells chondrocytes or medications like antibiotics) together with the Vivostat® PRF. In wound care we have seen excellent results when keratinocytes are applied together with the growth factors.

Vivostat® in wound treatment

Click on the video and see the Vivostat® System in use in wound treatment.

Vivostat® Co-Delivery

The revolutionary system makes it possible to co-apply e.g. stem cells or antibiotics with the Vivostat® product.

Vivostat® PRF

Using the Vivostat® System, you can prepare autologous platelets with multiple growth factors embedded in a matrix. 

Steenvoorde, P., Van Doorn, L. P., Naves, C. D., & Oskam, J. (2008), Use of autologous platelet-rich fibrin on hard-to-heal wounds, Journal of Wound Care, 17(2), 60–63, https://doi.org/10.12968/jowc.2008.17.2.28179

Larsson, G., & Löndahl, M. (2008). Comparative Study of two different treatment methods using autologous thrombocyte-fibrin treatment of diabetic foot ulcers. Presented at Jubileumsriksstämman.

Jørgensen, B., Löndahl, M., Larsson, G., & Monberg, H. (2008). Selected case stories, Vivostat® platelet rich fibrin (PRF®) in the treatment of chronic wounds. Sår.

Sommer, D. (2008). Use of autologous growth factors to heal chronic wounds. Forum Sanitas – The Informative Medical Magazine, 2008.

Ferraro, A. S., Lanti, A., Spurio, S. D., Marinacci, M., Del Proposto, G., Picardi, A., Cerretti, R., Dentamaro, T., Cupelli, L., De Fabritiis, P., Arcese, W., Adorno, G., & Isacchi, G. (2008). Platelet gel applications in oral mucositis in CGVHD. Presented at the European Hematology Association Congress.

Picardi, A., Cerretti, R., Cudillo, L., Lanti, A., Di Veroli, A., Ferraro, A., Mirabile, M., De Angelis, G., Di Caprio, L., Adorno, G., & Arcese, W. (2008). Application of PLTs gel for the treatment of refractory chronic GvHD skin lesions. Presented at the meeting European Group for Blood and Marrow Transplantation. 

Arenth, K. P., Schneider, C., & Ockert, D. (2009). Autologes thrombozytenreiches Fibrin – eine neue Möglichkeit zur Wundtherapie bei komplizierten chronischen Wunden. Wundtherapie bei komplizierten chronischen Wunden, 2009.

Monclús Fuertes E., Velasco Velasco R., Gómez-Escolar Larrañaga L., González Peirona E.  (2009), Our experience in the treatment of chronic ulcers using Vivostat PRF. Series of 10 cases, Cirugía Plástica IberoLatinoamericana, 35(2), 141-148

Löndahl, M. (2009). Clinical Experience of Vivostat® Platelet Rich Fibrin (PRF®) in the treatment of Diabetic foot ulcers. Presented at the 13eme Conference nationale des plaies et cicatrisations. 

Gipponi, M., Reboa, G., Testa, T., Giannini, G., & Strada, P. (2010), Tension-free primary closure with autologous platelet gel versus Vivostat- for the definitive treatment of chronic sacrococcygeal pilonidal disease, In Vivo Athens, Greece, 24(4), 583–589, https://pubmed.ncbi.nlm.nih.gov/20668329

Danielsen, P., Jørgensen, B., Karlsmark, T., Jørgensen, L. N., & Ågren, M. (2010). Effects of locally applied autologous Platelet-Rich Fibrin® (PRF®) on split-thickness skin graft donor sites. Presented at EWMA 2010.

Agren, M. S., Rasmussen, K., Pakkenberg, B., & Jorgensen, B.  (2014), Growth factor and proteinase profile of Vivostat platelet-rich fibrin linked to tissue repair, Vox Sanguinis, 107(1), 37–44, https://doi.org/10.1111/vox.12121

Bayer, A., Lammel, J., Rademacher, F., Groß, J., Siggelkow, M., Lippross, S., Klüter, T., Varoga, D., Tohidnezhad, M., Pufe, T., Cremer, J., Gläser, R., & Harder, J. (2016), Platelet-released growth factors induce the antimicrobial peptide human beta-defensin- 2 in primary keratinocytes, Experimental Dermatology, 25(6), 460–465, https://doi.org/10.1111/exd.12966

Johnstone, P., Kwei, J., Filobbos, G., Lewis, D., & Jeffery, S. (2017), Successful application of keratinocyte suspension using autologous fibrin spray, Burns, 43(3), e27–e30, https://doi.org/10.1016/j.burns.2016.05.010

Asmundsson, A., Löndahl, M., Dupros, I., Larson G., & Katzman, P. (N.D.). Platelet Rich Fibrin seems to be a safe and effective treatment in diabetic patients with lower extremity fistula

Steenvoorde, P., van Doorn, L., & Oskam, J. (N.D.). Vivostat PRF® for the treatment of hard-to-heal ischemic diabetic ulcer.

Fontein, D., Burger, M., Mannil, L., Giovanoli, P., & Plock, J. (N.D.). Evaluation of platelet-rich fibrin in deep dermal burn: a case study. Abstract presented at the 53rd Congress of Swiss Plastic Surgery.